Commission Offers Fixes To Speed Up EU Trials Of GMO-Containing ATMPs
Executive Summary
The European Commission is making use of opportunities available under existing legislation to help facilitate clinical trials of advanced therapy products containing genetically modified organisms.
You may also be interested in...
EU Sets Up Database Of National GMO Requirements To Facilitate ATMP Trials
The European Commission has developed a database to help drug companies navigate the complex process of seeking environmental clearance from EU member states before they can initiate a clinical trial with ATMPs containing a genetically modified organism.
Industry Welcomes EU Action Plan To Boost ATMP Development
An action plan produced by the European Medicines Agency and the European Commission has put forward a number of ideas for streamlining the processes for developing and assessing advanced therapy medicines, with the aim of speeding up the current sluggish rate of ATMP approvals. Industry says it will assess the proposals to see how well they address the key issues worrying the sector.
Gene Therapy Trials In EU Delayed By Environmental Considerations
Pharmaceutical companies in the EU are becoming keener to experiment with genetically-modified advanced therapy medicinal products in patients, but they are finding it hard to navigate through the maze of environmental risk assessment procedures in each member state.